China’s NMPA clears Akeso’s AK158D1 for Phase I trial in solid tumours
The development marks the fourth antibody-drug conjugate from Akeso to reach the clinical stage.
Analysis
View MoreAPIs to the rescue?
Oral bioavailability remains one of the biggest challenges in drug development, particularly for small-molecule APIs with poor solubility or permeability. Liam Critchley explores how pharmaceutical companies are using integrated formulation...
AI now: What QbD and PAT missed
Cool heads, smart chains
Sustainability vs suitability
Integrating sustainability compliance